Atorvastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress-related apoptosis. 2014

Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
*Medical School of Chinese People's Liberation Army, Chinese PLA General Hospital; †Department of Cardiology, Xuanwu Hospital, Capital Medical University; ‡Department of Pathophysiology, Chinese PLA General Hospital; §Department of Pathology, Beijing Chest Hospital, Capital Medical University; and ∥Department of Emergency, Chinese PLA General Hospital, Beijing, China.

The present study examined whether atorvastatin, when used for pharmacological postconditioning, attenuated myocardial ischemia-reperfusion (I/R) injury in a manner similar to ischemic postconditioning (I-PostC), that is, by inhibition of endoplasmic reticulum (ER) stress-related apoptosis. In the present study, markers for myocardial injury, infarct area, and hemodynamics, and indicators of ER stress and apoptosis were compared in ischemic and atorvastatin-induced postconditioning as a means of evaluating the protective effect of atorvastatin postconditioning in I/R injury and whether, as in I-PostC, inhibition of ER stress is involved. Both ischemic and atorvastatin-mediated postconditioning significantly decreased indications of cardiac damage and reduced serum concentrations of markers for myocardial injury, reduced the infarct area seen at the end of reperfusion, and improved left ventricular systolic function. We found that high-dose atorvastatin- and I-PostC significantly downregulated expression of glucose-regulating protein 78 and calreticulin (CRT; ER stress markers), expression of C/EBP homologous protein (CHOP), and caspase 12 (markers for ER stress-related apoptosis), and Bax (downstream molecule of CHOP), in the myocardial area at risk. Atorvastatin and I-PostC have similar cardioprotective effects in I/R injury and inhibit the ER stress-related apoptotic pathway.

UI MeSH Term Description Entries
D008297 Male Males
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D006538 Heptanoic Acids 7-carbon saturated monocarboxylic acids. Acids, Heptanoic
D000069059 Atorvastatin A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors. (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid,Atorvastatin Calcium,Atorvastatin Calcium Anhydrous,Atorvastatin Calcium Hydrate,Atorvastatin Calcium Trihydrate,Atorvastatin, Calcium Salt,CI 981,CI-981,Lipitor,Liptonorm,CI981
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015428 Myocardial Reperfusion Injury Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm. Reperfusion Injury, Myocardial,Injury, Myocardial Reperfusion,Myocardial Ischemic Reperfusion Injury,Injuries, Myocardial Reperfusion,Myocardial Reperfusion Injuries,Reperfusion Injuries, Myocardial
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D057775 Ischemic Postconditioning The application of repeated, brief periods of vascular occlusion at the onset of REPERFUSION to reduce REPERFUSION INJURY that follows a prolonged ischemic event. The techniques are similar to ISCHEMIC PRECONDITIONING but the time of application is after the ischemic event instead of before. Ischemic Post-Conditioning,Ischemic Post Conditioning,Post-Conditioning, Ischemic,Postconditioning, Ischemic

Related Publications

Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
May 2019, Biological & pharmaceutical bulletin,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
January 2014, International journal of clinical and experimental medicine,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
January 2022, PPAR research,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
January 2019, Journal of diabetes research,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
January 2021, Journal of inflammation research,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
December 2015, Experimental and molecular pathology,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
August 2013, Journal of cardiovascular pharmacology,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
April 2023, Cardiovascular drugs and therapy,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
January 2020, Respiratory medicine,
Jing-gang Xia, and Fei-fei Xu, and Yang Qu, and Dan-gan Song, and Hong Shen, and Xiu-hua Liu
January 2019, Drug design, development and therapy,
Copied contents to your clipboard!